| | Business Summary | | ICN
Pharmaceuticals,
Inc.
is
a
global,
research-based
pharmaceutical
company
that
develops,
manufactures,
distributes
and
sells
pharmaceutical,
research
and
diagnostic
products.
The
Company
distributes
and
sells
a
broad
range
of
prescription
(or
ethical)
and
over-the-counter
(OTC)
pharmaceutical
and
nutritional
products
in
over
90
countries.
These
pharmaceutical
products
treat
viral
and
bacterial
infections,
diseases
of
the
skin,
neuromuscular
disorders,
cancer,
cardiovascular
disease,
diabetes
and
psychiatric
disorders.
The
Company
operates
in
two
principal
business
areas,
the
pharmaceutical
business
and
the
biomedical
business. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | ICN
Pharmaceuticals
is
a
global
reasearch-based
pharmaceutical
company
that
develops,
manufactures,
distributes
and
sells
pharmaceuticals,
research
and
diagnostic
products.
For
the
six
months
ended
6/01,
revenues
rose
5%
to
$404.7
million.
Net
income
before
extraordinary
item
fell
27%
to
$42.5
million.
Revenues
benefited
from
acquisitions
and
sales
growth
of
Efudex(R)
and
Mestinon.
Earnings
were
offset
by
a
reduced
operating
margin
and
a
higher
effective
tax
rate. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Milan Panic, 71
Chairman
and CEO | $1.5M | -- | Adam Jerney, 59
Pres,
COO | 726K | $4.3M | Richard Meier, 41
CFO,
Exec. VP | 488K | 373K | John Giordani, 58
Exec.
VP, Controller | 501K | 910K | Gregory Keever
Exec.
VP, Gen. Counsel | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/i/icn.gif)